HDFC Life Insurance Q1 Results Highlights: Net Profit Iumps 15% on-year to ₹479 cr
Torrent Pharma Q1 Results FY2023, PAT at Rs. 354 crores
Last Updated: 10th December 2022 - 03:16 pm
On 29th July 2022, Torrent Pharma announced its quarterly results for the first quarter of FY2023.
Q1FY23 Key Highlights:
- The company reported its Revenue at Rs. 2,347 crores up by 10%.
- The Gross margins were at 72% and EBITDA margins at 32%.
- EBITDA stood at Rs. 742 crores and was up by 3%.
- Net profit after tax at Rs. 354 crores was up by 7%.
Geographical Highlights:
India:
- Indian market revenues were at Rs. 1,245 crores grew by 14%.
- As per secondary market data (AIOCD), Torrent’s Q1 FY23 growth was 17% versus IPM growth of 2%
- Strong outperformance of top brands together with new launches continued to drive market share gains across focus therapies.
- During the quarter, Torrent added 300 MRs bringing the total field force strength to 4,200
Brazil:
- Brazil's revenue at Rs 184 crores, up by 20%.
- Constant currency revenue at R$ 117 million was up by 8%.
- Adjusted for the discontinued tender business in the previous year, the growth is 10%.
- As per secondary market data, Torrent’s Q1 growth of 10% was in line with market growth.
- Growth was aided by strong growth in the generic segment, the performance of top brands, and new launches.
United States:
- US revenue at Rs 299 crores, up by 13%.
- Constant currency revenue at $39 million was up by 7%.
- Revenue was complemented by the performance of Dapsone launched in the previous quarter.
- As of June 30, 2022, 60 ANDAs were pending approval with USFDA, and 3 tentative approvals were received. During the quarter, 1 ANDAs was filed.
Germany:
- Germany's revenue stood at Rs 214 crores, down by 18%.
- Constant currency revenue were Euro 26 million.
- Growth was adversely impacted due increase in competition and loss of tenders in previous quarters.
- Torrent has already initiated measures to improve price competitiveness.
- Flat ₹20 Brokerage
- Next-gen Trading
- Advance Charting
- Actionable Ideas
Trending on 5paisa
05
Tanushree Jaiswal
Corporate Actions Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.